Specializing in biological safety and quality testing, TFBS (Testing Facility for Biological Safety) Bioscience Inc. is Taiwan’s first contract research organization in this field.
TFBS was established 10 years ago as a business unit in the Development Center of Biotechnology, a leading life-science research institute in Taiwan. The company offers reliable, cost-effective and scientifically validated testing solutions for biopharmaceutical companies worldwide.
“We are well-positioned to deliver value-added services and solutions to our clients in Taiwan, Japan and the rest of the region,” said Dr. Thomas Yuan, TFBS CEO and founder.
Japan is a world leader in research and development of small molecule drugs and cell therapy and is now taking steps to strengthen its biologics development.
In 2017, the U.S. Food and Drug Administration historically approved the first two products of CAR-T (chimeric antigen receptor) cell therapy and the first product of gene therapy. “We expect to see more efforts and activities devoted to these fields in Japan, while TFBS is targeted to provide services of GMP (good manufacturing practice) virus production and testing in 2018,” explained Yuan.
TFBS aims to become a center of excellence for virus testing and production in Asia. Sixteen percent of TFBS’s clients are Japanese — Yuan aims to increase this to 50 percent in the next two years in line with the development of Japan’s biopharmaceutical industry.
“While meeting the biological safety and quality requirements of Japan’s regulatory authorities, TFBS is committed to strengthening our relationships with our Japanese clients,” concluded Yuan.
“In the coming age of cell and gene therapy, we look forward to providing our Japanese clients with solutions for their needs in the production of viruses at our cutting-edge GMP-compliant P2 facility.”
